Author:
Zhang Miaoying,Chen Xiuli,Shen Shuixian,Li Tang,Chen Linqi,Hu Min,Cao Lingfeng,Cheng Ruoqian,Zhao Zhuhui,Luo Feihong
Abstract
AbstractThe pathogenic base of neonatal diabetes mellitus (NDM) is highly heterogeneous. Sulfonylurea (SU) has been successfully applied in majority of NDM patients with KWe identified 16 patients with NDM. These patients underwent SU titration and were followed after successful SU monotherapy. All patients were sequenced for all exons and adjacent intron-exon junctions ofOf the 16 patients, 15 (94%) reached glycemic goal (7–10 mmol/L) after SU monotherapy except one patient with theOur study showed that SU monotherapy resulted in satisfactory glycemic control in most of the patients with NDM whose genetic defects are heterogeneous. The usage of SU may be considered as first-line therapy for patients with NDM in developing countries where effective genetic screening is not established.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference56 articles.
1. Mutations in ATP sensitive channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood;Flanagan;Diabetes,2007
2. Neonatal diabetes mellitus;Aguilar;Endocr Rev,2008
3. Predicted structural alterations in proinsulin during its interactions with prohormone convertases;Lipkind;Biochemistry,1999
4. th rd Cloning of the beta cell high - affinity sulfonylurea receptor : a regulator of insulin secretion;Aguilar;Science,1995
5. labeling and exposure in neonates;Laughon;Drug JAMA,2014
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献